Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% HigherThe Motley Fool • 12/02/24
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsInvestors Business Daily • 11/14/24
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And OpdivoBenzinga • 11/04/24
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil SalesZacks Investment Research • 10/31/24
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024Business Wire • 10/30/24
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024Business Wire • 10/23/24
Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You?The Motley Fool • 10/22/24
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit TherapeuticsThe Motley Fool • 10/13/24
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street AnalystsThe Motley Fool • 10/07/24
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLCBusiness Wire • 10/03/24